The Congressionally Directed Medical Research Programs (CDMRP) announces new FY24 Research Funding Opportunities spanning the research spectrum from mechanistic research to clinical trials and that are now available in Rare Disease research areas. More information: https://cdmrp.health.mil/funding/default. All organizations, institutions and companies, both international and domestic, are encouraged to apply.
Just two months until application submission – FDA Office of Orphan Products Development Natural History Studies grant funding opportunity
The grant application submission deadline is coming up in just 2 months! The application submission deadline for this grant funding opportunity is February 13, 2024. Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) The purpose of this grant is to support efficient and innovative natural history studies that advance medical product development in rare […]
FDA Office of Orphan Products Development: Natural History Studies grant funding opportunity
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) announces the availability of funds for fiscal year (FY) 2024 to support natural history studies for rare diseases and conditions. This funding opportunity is intended to support prospective or retrospective, efficient, and innovative natural history studies with a focus on collaborative and standardized approaches to […]
New funding opportunity from NIH: IND-enabling Studies for Platform Clinical Trials of Genome Editing in Multiple Diseases
The US National Institutes of Health (NIH) published a new Notice of Funding Opportunity (NOFO) with the aim to provide support for applications for IND-enabling studies for the development of a novel in vivo genome editing therapeutic platform (genome editor plus delivery system) for two or more disease indications, using the same genome editor, route of administration, and […]
Announcement of upcoming FDA Office of Orphan Products Development Natural History Studies grant funding opportunity
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal year (FY) 2024 to support natural history studies for rare diseases and conditions. This funding opportunity is intended to support prospective or retrospective, efficient, and innovative natural history studies with a focus on collaborative […]
FDA – Announcement of a Grant Funding Opportunity for Rare Disease Research
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2023 – 2025 to support clinical trials for rare diseases and conditions. The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in support of a new […]
FDA: Announcement of New Grant Funding Opportunity for Rare Disease Research
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2023 – FY 2025 to support clinical trials for rare diseases and conditions. The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in support of a […]
Announcement of New Grant Funding Opportunity for Rare Disease Research
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2023 – FY 2025 to support clinical trials for rare diseases and conditions. The purpose of this funding opportunity announcement is to fund clinical trials of products evaluating efficacy and/or safety in […]
Notice of Upcoming Funding Opportunity: National Pediatric Rare Disease Clinical Trials and Treatment Network
The Canadian Institute of Health Research – Institute of Genetics is pleased to announce the upcoming funding opportunity “National Pediatric Rare Disease Clinical Trials and Treatment Network”. The specific objectives of this funding opportunity are to: Develop a platform to support pediatric rare disease clinical trials in Canada; Increase the capacity to perform rare disease […]
Canadian Organization for Rare Disorders welcomes federal funding for rare drug plan to accelerate access to diagnostics and treatments
On March 22, 2023, the Canadian Federal Government announced the launch of Canada’s Rare Disease Drug Strategy with a $1.5 billion commitment over three years to “improve access to new and emerging drugs, as well as support enhanced access to existing drugs, early diagnosis, and screening for rare diseases, and to improve the collection and […]